Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix

Journal of Pathology

Volumn 189, Issue 2, 1999, Pages 245-250

  Riethdorf, Lutz ^a,b   Riethdorf, Sabine ^a   Petersen, Sonja ^a   Bauer, Michael ^c   Herbst, Hermann ^b   Jänicke, Fritz ^a   Löning, Thomas ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

HPV; Microinvasive carcinoma; Plasminogen activating system; Squamous cell lesions; Uterine cervix

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER INVASION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; VIRUS INFECTION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR VIRUS INFECTIONS; URINARY PLASMINOGEN ACTIVATOR; UTERINE CERVICAL NEOPLASMS;

EID: 0032861405     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199910)189:2<245::AID-PATH427>3.0.CO;2-Z     Document Type: Article

References (37)

1. Crawford HC, Matrisian LN. Tumor and stromal expression of matrix metallo-proteinases and their role in tumor progression. Invasion Metastasis 1994; 14: 234-245.
2. Matrisian LN. The matrix-degrading metalloproteinases. Bioassays 1992; 14: 455-463.
3. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2: 613-618.
4. Duffy MJ. Cancer metastasis: biological and clinical aspects. Ir J Med Sci 1998; 167: 4-8.
5. Waltz DA, Natkin LR, Fujita RM, et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 58-67.
6. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
7. Ganesh S, Sier CFM, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-4071.
8. Allgayer H, Babic R, Grützner KU, et al. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998; 16: 62-73.
9. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994; 73: 1398-1405.
10. Hewin DF, Savage PB, Alderson D, Vipond MN. Plasminogen activators in oesophageal carcinoma. Br J Surg 1996; 83: 1152-1155.
11. Hofman R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996; 78: 487-492.
12. Gleeson NC, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer 1993; 72: 1670-1672.
13. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
14. Schmitt M, Jänicke F, Graeff H. Tumor associated proteases. Fibrinolysis 1992; 6: 3-26.
15. Jänicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-2530.
16. Fersis N, Kaufmann M, Kramer MD, Wittmann G, Wallwiener D, Bastert G. Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast carcinoma. Geburtshilfe Frauenheilkd 1996; 56: 28-34.
17. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184: 9-13.
18. Riethdorf L, Riethdorf S, Gützlaff K, Prall F, Löning T. Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol 1996; 149: 1469-1476.
19. Ginsburg D, Zeheb R, Yang AY, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-1680.
20. Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A 1984; 81: 5355-5359.
21. Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A 1984; 81: 4727-4731.
22. Herbst H, Wege T, Milani S, et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150: 1647-1659.
23. Aznavoorian S, Murphy AN. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368-1383.
24. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994; 54: 6539-6548.
25. Fujishiro S, Kobayashi H, Terao T. Urokinase-type plasminogen activator as a predictor for lymph node metastasis of uterine cervical cancer. Nippon Sanka Fujinka Gakkai Zasshi 1994; 46: 129-136.
26. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Tagagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistocheraical study. Am J Gastroenterol 1993; 88: 1928-1933.
27. Ito H, Yonemura Y, Fujita H, et al. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 1996; 427: 487-496.
28. 2-macroglobulin receptor in human breast carcinomas. Int J Cancer 1996; 66: 441-452.
29. Itaya T, Suzuki K, Tagaki I, Motai H, Baba S. Relationship between head and neck squamous cell carcinomas and fibrinolytic factors. Immunohistochemical study. Acta Otolaryngol Suppl Stockholm 1996; 525: 113-119.
30. Constantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-I is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996; 77: 1079-1088.
31. Koretz K, Möller P, Schwartz-Albiez R. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumor cells. Eur J Cancer 1993; 29: 1184-1189.
32. Damjanovich L, Turzo C, Adany R. Factors involved in the plasminogen activation system in human breast tumours. Thromb Haemost 1994; 71: 684-691.
33. Buo L, Bjornland K, Karlsrud TS, et al. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines. Anticancer Res 1994; 14: 2445-2451.
34. Bolon I, Devouassoux M, Robert C, Moro D, Brambilla C, Brambilla E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 1997; 150: 1619-1629.
35. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 1995; 60: 597-603.
36. Wagner SN, Atkinson MJ, Thanner S, et al. Type-1 plasminogen activator inhibitor in human renal cell carcinoma. J Pathol 1996; 179: 95-99.
37. Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 1997; 183: 388-397.